Scarica l'app Stockscreener
6.15
3.15%
-0.20
Dopo l'orario di chiusura:
6.15
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$6.35
Aprire:
$6.48
Volume 24 ore:
633.24K
Relative Volume:
0.74
Capitalizzazione di mercato:
$419.74M
Reddito:
$46.02M
Utile/perdita netta:
$-70.80M
Rapporto P/E:
-3.3791
EPS:
-1.82
Flusso di cassa netto:
$-1.61M
1 W Prestazione:
-5.38%
1M Prestazione:
-19.40%
6M Prestazione:
-32.04%
1 anno Prestazione:
-76.91%
Intervallo 1D:
$6.05
$6.55
Intervallo di 1 settimana:
$6.05
$7.59
Portata 52W:
$5.90
$29.31
Eyepoint Pharmaceuticals Inc Stock (EYPT) Company Profile
Nome
Eyepoint Pharmaceuticals Inc
Settore
Industria
Telefono
617-926-5000
Indirizzo
480 PLEASANT STREET, WATERTOWN, MA
Confronta EYPT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
EYPT
Eyepoint Pharmaceuticals Inc
|
6.15 | 419.74M | 46.02M | -70.80M | -1.61M | -1.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Eyepoint Pharmaceuticals Inc Stock (EYPT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-01-07 | Iniziato | Citigroup | Buy |
| 2024-10-16 | Iniziato | Scotiabank | Sector Outperform |
| 2024-08-28 | Iniziato | Jefferies | Buy |
| 2024-01-22 | Iniziato | JP Morgan | Overweight |
| 2023-11-02 | Iniziato | Mizuho | Buy |
| 2023-04-21 | Iniziato | Robert W. Baird | Outperform |
| 2022-07-07 | Iniziato | Chardan Capital Markets | Buy |
| 2021-03-01 | Iniziato | Cowen | Outperform |
| 2021-01-28 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-04-06 | Downgrade | B. Riley FBR | Buy → Neutral |
| 2019-11-04 | Ripresa | Laidlaw | Buy |
| 2019-09-12 | Iniziato | Guggenheim | Buy |
Mostra tutto
Eyepoint Pharmaceuticals Inc Borsa (EYPT) Ultime notizie
EyePoint Pharmaceuticals (EYPT) Reports Q2 Loss, Misses Revenue Estimates - MSN
Adversity is less terrifying than hope: EyePoint Pharmaceuticals Inc (EYPT) - SETE News
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - The Manila Times
EyePoint Pharmaceuticals Grants Stock Options to New Employees as Inducement Awards - Nasdaq
(EYPT) Trading Advice - Stock Traders Daily
230,745 Shares in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Bought by abrdn plc - MarketBeat
TD Cowen maintains EyePoint stock Buy rating, $20 target - MSN
Brokerages Set EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Target Price at $26.63 - MarketBeat
EyePoint Pharmaceuticals (NASDAQ:EYPT) Earns "Buy" Rating from Chardan Capital - MarketBeat
EyePoint Pharmaceuticals (NASDAQ:EYPT) Reaches New 52-Week LowTime to Sell? - MarketBeat
EyePoint Pharmaceuticals (NASDAQ:EYPT) Earns Buy Rating from Chardan Capital - Armenian Reporter
EyePoint's decline following positive data makes no sense, says analyst - MSN
EyePoint Pharmaceuticals Inc [EYPT] Shares Fall Approximately -76.18% Over the Year - Knox Daily
EyePoint Pharmaceuticals (NASDAQ:EYPT) Receives Buy Rating from Chardan Capital - Armenian Reporter
Investors unsure on EyePoint’s Duravyu blockbuster claim - The Pharma Letter
A significant driver of top-line growth: EyePoint Pharmaceuticals Inc (EYPT) - SETE News
There Is A Lot Of Upside Potential For EyePoint Pharmaceuticals Inc(NASDAQ: EYPT) - Stocks Register
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Given Consensus Recommendation of “Buy” by Analysts - ETF Daily News
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Given Average Recommendation of “Buy” by Analysts - Defense World
EyePoint stock jumps 10% on Duravyu study results - MSN
(EYPT) Investment Analysis - Stock Traders Daily
Analyzing the Impact of Earnings Reports on EyePoint Pharmaceuticals Inc Inc. (EYPT) Price Performance - The InvestChronicle
Short Interest in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Rises By 9.9% - MarketBeat
EyePoint Pharmaceuticals : Investor Presentation February 2025 - Marketscreener.com
EyePoint stock jumps 10% on Duravyu study results (EYPT:NASDAQ) - Seeking Alpha
EyePoint's Phase 2 Trial of Duravyu to Treat Diabetic Macular Edema Meets Endpoints; Shares Still Slump Pre-Bell - Marketscreener.com
Collegium Appoints Nancy S. Lurker to its Board of Directors - citybiz
EyePoint’s decline following positive data makes no sense, says analyst By Investing.com - Investing.com Nigeria
EyePoint's decline following positive data makes no sense, says analyst By Investing.com - Investing.com South Africa
Pharma Veteran Nancy Lurker Joins Collegium Board: Ex-Novartis CMO Brings M&A Expertise - StockTitan
EyePoint Announces Positive Six-Month Results for the Phase 2 VERONA Clinical Trial of DURAVYU™ for Diabetic Macular Edema Meeting Primary and Secondary Endpoints - The Manila Times
EyePoint Pharmaceuticals stock sinks following clinical trial results By Investing.com - Investing.com South Africa
Should investors be concerned about EyePoint Pharmaceuticals Inc (EYPT)? - US Post News
EyePoint Pharmaceuticals stock sinks following clinical trial results - Investing.com
Clinical Trial Success: EyePoint's DME Drug Reduces Treatment Burden by Two-Thirds - StockTitan
Analyzing EyePoint Pharmaceuticals Inc (EYPT) After Recent Trading Activity - Knox Daily
Financial Health Report: EyePoint Pharmaceuticals Inc (EYPT)’s Ratios Tell a Tale - The Dwinnex
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Short Interest Update - Defense World
EyePoint: A Risky 'Buy' Ahead Of Key Readout For Long-Acting Eylea Rival (NASDAQ:EYPT) - Seeking Alpha
EyePoint Pharmaceuticals' CEO Jay S. Duker to Speak at Guggenheim SMID Cap Biotech Conference on February 6, 2025 - Nasdaq
EyePoint to Present at Guggenheim SMID Cap Biotech Conference - The Manila Times
Inside EyePoint's Strategy: CEO Set to Reveal Latest Developments in Retinal Disease Treatment - StockTitan
Franklin Resources Inc. Expands Portfolio with EyePoint Pharmace - GuruFocus.com
Long Term Trading Analysis for (EYPT) - Stock Traders Daily
Strong week for EyePoint Pharmaceuticals (NASDAQ:EYPT) shareholders doesn't alleviate pain of one-year loss - Yahoo Finance
Brokers Offer Predictions for EYPT FY2025 Earnings - Defense World
EyePoint Pharmaceuticals (NASDAQ:EYPT) Trading 6.1% HigherShould You Buy? - MarketBeat
Research Analysts Issue Forecasts for EYPT FY2025 Earnings - MarketBeat
Eyepoint Pharmaceuticals Inc Azioni (EYPT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Eyepoint Pharmaceuticals Inc Azioni (EYPT) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Lurker Nancy | Director |
Feb 09 '25 |
Option Exercise |
0.00 |
20,000 |
0 |
205,436 |
| Duker Jay S. | President and CEO |
Feb 09 '25 |
Option Exercise |
0.00 |
7,000 |
0 |
79,706 |
| Elston George | Chief Financial Officer |
Jan 06 '25 |
Option Exercise |
0.00 |
15,285 |
0 |
73,374 |
| Elston George | Chief Financial Officer |
Jan 05 '25 |
Option Exercise |
0.00 |
15,000 |
0 |
63,356 |
| Lurker Nancy | Director |
Jan 06 '25 |
Option Exercise |
0.00 |
75,134 |
0 |
185,436 |
| Lurker Nancy | Director |
Jan 05 '25 |
Option Exercise |
0.00 |
12,667 |
0 |
110,302 |
| Landis John B. | Director |
Jan 05 '25 |
Option Exercise |
0.00 |
10,000 |
0 |
21,400 |
| Duker Jay S. | President and CEO |
Jan 06 '25 |
Option Exercise |
0.00 |
20,794 |
0 |
78,814 |
| Duker Jay S. | President and CEO |
Jan 05 '25 |
Option Exercise |
0.00 |
30,000 |
0 |
68,027 |
0.27%
3.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):